A new microfluidic device has been developed to enhance the diagnosis of lung cancer by improving the detection of tumor cells in pleural effusions. This device, created by researchers from Southeast University, Wuxi University of Technology, and Zhongda Hospital of Southeast University, uses a unique approach to separate and enrich tumor cells, even in the presence of overwhelming numbers of background blood cells.
The device operates through two linked sorting steps. In the first stage, small blood cells are driven towards the sidewalls and removed through waste outlets, while larger target cells remain near the core stream for collection. In the second stage, the balance of inertial lift, Dean drag, and local vortex-induced forces separates single tumor cells from larger clusters according to size. This method allows for the recovery of both single tumor cells and intact clusters, providing a more comprehensive view of the tumor's characteristics.
In simulated cell tests, the system demonstrated impressive recovery rates of 91.8% ± 6.6% for 25 µm particles representing clusters and 87.4% ± 7.4% for 15 µm particles representing single tumor cells. When applied to actual patient samples, the chip processed 50 mL in 6.5 minutes at 8 mL/min, achieving 68% purity for single MTCs and 35% purity for intact MTCCs. Tumor cells were identified using immunofluorescence techniques, confirming their presence as DAPI+/Pan-CK+/CD45−.
The significance of this device lies in its ability to provide a clearer picture of both tumor burden and metastatic behavior. By retaining intact clusters while reducing background blood cells, it offers a more accurate assessment of malignancy. This is particularly valuable as it allows clinicians to gain a fuller understanding of the tumor's characteristics, including the presence of clusters, which may be missed in conventional detection strategies that focus solely on isolated cells.
Furthermore, the device's label-free nature, compatibility with standard downstream staining and microscopic analysis, and its potential for scalable, low-cost manufacturing make it a promising tool for clinical use. However, the authors emphasize the need for further clinical validation with larger patient cohorts to establish its diagnostic sensitivity and prognostic value.
In summary, this innovative microfluidic device represents a significant advancement in the field of cancer diagnosis, offering a faster, more accurate, and less disruptive method for enriching tumor cells from pleural effusions. It has the potential to revolutionize liquid-biopsy analysis and provide valuable insights into the characteristics of lung cancer, ultimately improving patient care and outcomes.
